GAB1 has been described to be involved in alectinib resistance mediated by activation of the HGF/MET signaling pathway in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer [130]. The gene discussed is GAB1; the disease is non-small cell lung carcinoma.